Reactome | C-ter TLR7 dimer binds imiquimod

C-ter TLR7 dimer binds imiquimod

Stable Identifier

R-HSA-9724670

Type

Reaction [binding]

Species

Homo sapiens

Compartment

cytosol, endosome membrane

ReviewStatus

5/5

Locations in the PathwayBrowser

Expand all

General

SBML | | PDF

SVG | | PPTX | SBGN

Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

Activation of toll-like receptor 7 (TLR7) leads to secretion of cytokines (interferon-alpha, interleukin-6, tumor-necrosis-factor alpha) by immune cells. Stimulation of the innate immune system by the TLR7 agonist imiquimod is used in the therapy of squamous and basal cell carcinoma, as well as skin conditions like genital herpes, keratinosis and warts. Its side effects include local inflammatory reactions and systemic reactions like fever, headache, and tiredness (Miller et al, 1999; Gaspari et al, 2009; Hanna et al, 2016).

Literature References

PubMed ID	Title	Journal	Year
19537370	Beyond a decade of 5% imiquimod topical therapy Rosen, T, Tyring, SK, A Gaspari, A	J Drugs Dermatol	2009
27387373	Imiquimod in dermatology: an overview Abadi, R, Abbas, O, Hanna, E	Int J Dermatol	2016
29152046	Design and Synthesis of N1-Modified Imidazoquinoline Agonists for Selective Activation of Toll-like Receptors 7 and 8 Olin, M, Xiong, Z, Kucaba, TA, Larson, P, Griffith, TS, Ferguson, DM	ACS Med Chem Lett	2017
10411278	Imiquimod applied topically: a novel immune response modifier and new class of drug Miller, RL, Tomai, MA, Gerster, JF, Owens, ML, Slade, HB	Int J Immunopharmacol	1999